{
  "id": "601f08c11cb411341a00006c",
  "type": "factoid",
  "question": "What drug, used to treat rheumatoid arthritis, is an interleukin-1 receptor antagonist?",
  "ideal_answer": "Anakinra is an oral interleukin-1 receptor antagonist that is used to treat rheumatoid arthritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12932294",
    "http://www.ncbi.nlm.nih.gov/pubmed/11776280",
    "http://www.ncbi.nlm.nih.gov/pubmed/15984903",
    "http://www.ncbi.nlm.nih.gov/pubmed/29883212",
    "http://www.ncbi.nlm.nih.gov/pubmed/15965816",
    "http://www.ncbi.nlm.nih.gov/pubmed/31818504",
    "http://www.ncbi.nlm.nih.gov/pubmed/20476905",
    "http://www.ncbi.nlm.nih.gov/pubmed/21881988",
    "http://www.ncbi.nlm.nih.gov/pubmed/12504237",
    "http://www.ncbi.nlm.nih.gov/pubmed/12715722",
    "http://www.ncbi.nlm.nih.gov/pubmed/30859382",
    "http://www.ncbi.nlm.nih.gov/pubmed/14989428",
    "http://www.ncbi.nlm.nih.gov/pubmed/12563672",
    "http://www.ncbi.nlm.nih.gov/pubmed/12196041",
    "http://www.ncbi.nlm.nih.gov/pubmed/12928941",
    "http://www.ncbi.nlm.nih.gov/pubmed/16269431",
    "http://www.ncbi.nlm.nih.gov/pubmed/12687534",
    "http://www.ncbi.nlm.nih.gov/pubmed/15082469",
    "http://www.ncbi.nlm.nih.gov/pubmed/12510368",
    "http://www.ncbi.nlm.nih.gov/pubmed/29553981",
    "http://www.ncbi.nlm.nih.gov/pubmed/20703489",
    "http://www.ncbi.nlm.nih.gov/pubmed/15172046",
    "http://www.ncbi.nlm.nih.gov/pubmed/15201943"
  ],
  "snippets": [
    {
      "text": "Anakinra is an anti-IL-1RA targeting IL-1\u03b2 with a central role in the occurrence of auto-inflammatory diseases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818504",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(1) Anakinra is an interleukin-1 receptor antagonist (IL-1ra), which blocks interleukin-1 (IL-1), a protein involved in the inflammation and the joint destruction associated with rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11776280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15201943",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15172046",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "One of these molecules is interleukin-1 receptor antagonist (Anakinra; Amgen Corp.).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29553981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: The anti-interleukin-1 receptor antagonist, anakinra, was approved for the treatment of rheumatoid arthritis (RA) more than 12\u00a0ye",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29883212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra, the recombinant form of IL-1 receptor antagonist (IL-1Ra), has been approved for clinical use in the treatment of rheumatoid arthritis as the drug Kineret trade mark, but it must be administered daily by subcutaneous injection. Gene ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12932294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The efficacy and safety of anakinra, a recombinant human interleukin 1 (IL1) receptor antagonist used in rheumatoid arthritis, has been documented in five randomised controlled st",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16269431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ") Anakinra is an interleukin-1 receptor antagonist (IL-1ra), which blocks interleukin-1 (IL-1), a protein involved in the inflammation and the joint destruction associated with rheumatoid arthritis (RA). (2) The ma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11776280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The use of further biologicals, the interleukin-1 receptor antagonist Anakinra, Atlizumab (MRA) blocking the receptor for interleukin-6 or Abatacept, an inhibitory ligand of the co-stimulatory T cell membrane molecule CD28, remain experimental and should be preserved for clinical studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15965816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra is a specific receptor antagonist of interleukin-1 that differs from naturally occurring interleukin-1 receptor antagonist by the presence of a methionine group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20476905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, is the first biological agent approved to block the pro-inflammatory effects of IL-1 in patients with rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12196041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Anakinra, an interleukin-1 receptor antagonist and tocilizumab, an interleukin-6 receptor blocker, are used for the treatment of rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30859382",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first IL-1 antagonist to be approved for RA was Anakinra, an IL-1 receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703489",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two randomized, multicenter clinical trials with anakinra, a recombinant IL-1 receptor antagonist (rHHHuIL-1Ra), revealed that application of anakinra with or without methotrexate induces remission (ACR 20) in 38-71% of patients with RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12715722",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra (Kineret) is an IL-1 receptor antagonist that blocks the biologic activity of IL-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15172046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12563672",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This study evaluated the benefit of anakinra, a human recombinant form of interleukin 1 receptor antagonist, on the functional status of patients with active rheumatoid arthritis (RA) despite taking maximally tolerated doses of methotrexate (MTX).M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12563672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate the safety of anakinra (a recombinant human interleukin-1 receptor antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those seen in clinical practice.M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12687534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra, a recombinant human interleukin-1 receptor antagonist offers a new potent treatment for rheumatoid arthritis(RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12510368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1ra) recently approved by the FDA as a new therapy for patients with rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14989428",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12510368",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14989428",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: Interleukin -1 receptor antagonist ( IL-1Ra ) is a new option among biotherapies against rheumatoid arthritis ( RA ).THE AIM: of this review is to recall the rationale of use of IL-1Ra and to analyse the results available in the current literature.CURRENT KNOWLEDGE AND KEY POINTS: Pathophysiological data of RA give a specific position for IL-1 as a potential target for immuno",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12504237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra (Kineret) is the first biologic drug that has been developed specifically as an interleukin (IL)-1 receptor antagonist (Ra) and is derived from an endogenous IL-1Ra.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15984903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12687534",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To evaluate the safety of anakinra (a recombinant human interleukin-1 receptor antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those seen in clinical practice.METHODS: A total of 1,414 patients were randomly assigned to treatment with 100 mg of anakinra or placebo, administered daily by sub",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12687534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA).METHODS: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, place",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15082469",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12928941",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "anakinra, anti-il-1ra"
}